Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors

Brigatinib produced responses in 23% of all tumors in patients with NF2-related tumors (schwannomas, meningiomas, and ependymomas), with hearing improvement in approximately one third of patients.

​   The New England Journal of Medicine: Search Results in Neurology/Neurosurgery